BRAT1 Antilichaam - C-terminalgebied: FITC (ARP62762 P050-FITC)

BRCA1-associated ATM activator 1

BAAT1, RMFSL, NEDCAS, C7orf27

221927

Q6PJG6

NP_689956

Human

The immunogen is a synthetic peptide directed towards the C-terminal region of Human BRAT1

The protein encoded by this ubiquitously expressed gene interacts with the tumor suppressing BRCA1 (breast cancer 1) protein and and the ATM (ataxia telangiectasia mutated) protein. ATM is thought to be a master controller of cell cycle checkpoint signalling pathways that are required for cellular responses to DNA damage such as double-strand breaks that are induced by ionizing radiation and complexes with BRCA1 in the multi-protein complex BASC (BRAC1-associated genome surveillance complex) . The protein encoded by this gene is thought to play a role in the DNA damage pathway regulated by BRCA1 and ATM.

UBC; BRCA1; USP48; VCP; ATM; SUMO2

FITC: Fluorescein Isothiocyanate

Polyclonal Antibody

WB

Affinity Purified

0.5 mg/ml

Human: 100%

Liquid. Purified antibody supplied in 1x PBS buffer.

All conjugated antibodies should be stored in light-protected vials or covered with a light protecting material (i.e. aluminum foil) . Conjugated antibodies are stable for at least 12 months at 4C. If longer storage is desired (24 months), conjugates may be diluted with up to 50% glycerol and stored at -20C to -80C. Freezing and thawing conjugated antibodies will compromise enzyme activity as well as antibody binding.

87kDa

Wet Ice

821

BRAT1

BRAT1

Rabbit

BRCA1-associated ATM activator 1

NM_152743

FDCDRPVAQKSCDLLLFLRDKIASYSSLREARGSPNTASAEATLPRWRAG